Kepler Capital Markets Lowers Qiagen (NYSE:QGEN) to Reduce

Kepler Capital Markets cut shares of Qiagen (NYSE:QGEN) from a hold rating to a reduce rating in a research note issued to investors on Wednesday, BenzingaRatingsTable reports.

Several other equities analysts also recently weighed in on the company. Exane BNP Paribas upgraded Qiagen from a neutral rating to an outperform rating in a research report on Friday, July 12th. DZ Bank restated a neutral rating on shares of Qiagen in a research report on Wednesday, July 24th. BNP Paribas upgraded Qiagen from a neutral rating to an outperform rating in a research report on Friday, July 12th. Berenberg Bank restated a buy rating on shares of Qiagen in a research report on Tuesday, October 1st. Finally, Barclays downgraded Qiagen from an overweight rating to an equal weight rating in a research report on Tuesday. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $36.88.

NYSE QGEN traded up $0.91 on Wednesday, hitting $27.26. 36,237 shares of the company traded hands, compared to its average volume of 1,115,450. The company has a market capitalization of $7.23 billion, a price-to-earnings ratio of 20.16, a P/E/G ratio of 2.09 and a beta of 0.85. The company has a current ratio of 1.77, a quick ratio of 1.59 and a debt-to-equity ratio of 0.54. The business’s 50 day moving average price is $33.41 and its 200-day moving average price is $37.48. Qiagen has a 52-week low of $25.04 and a 52-week high of $41.55.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, July 24th. The company reported $0.33 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.34 by ($0.01). The company had revenue of $381.60 million for the quarter, compared to analysts’ expectations of $386.37 million. Qiagen had a net margin of 12.94% and a return on equity of 12.10%. Qiagen’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.33 earnings per share. As a group, sell-side analysts predict that Qiagen will post 1.39 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in the company. BB&T Securities LLC increased its holdings in shares of Qiagen by 5.0% in the second quarter. BB&T Securities LLC now owns 10,591 shares of the company’s stock worth $429,000 after purchasing an additional 503 shares during the last quarter. Private Capital Group LLC increased its holdings in shares of Qiagen by 354.0% in the second quarter. Private Capital Group LLC now owns 681 shares of the company’s stock worth $25,000 after purchasing an additional 531 shares during the last quarter. Riverhead Capital Management LLC increased its holdings in shares of Qiagen by 17.2% in the second quarter. Riverhead Capital Management LLC now owns 3,750 shares of the company’s stock worth $152,000 after purchasing an additional 550 shares during the last quarter. Phocas Financial Corp. bought a new stake in shares of Qiagen in the second quarter worth about $2,259,000. Finally, Ossiam increased its holdings in shares of Qiagen by 1.5% in the second quarter. Ossiam now owns 40,695 shares of the company’s stock worth $1,654,000 after purchasing an additional 609 shares during the last quarter. Institutional investors and hedge funds own 62.10% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Further Reading: What is the strike price in options trading?

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.